We thank Dr Risch for pointing out that our study provides important information about prediagnosis aspirin use and risk of pancreatic cancer.1 We agree that a quantitative summary of all prior studies was not undertaken as part of this analysis. The primary aims of our work were to evaluate the prediagnosis use of aspirin and nonsteroidal anti-inflammatory drugs in 2 large, prospective cohorts and investigate prediagnosis plasma salicylurate levels and risk of pancreatic cancer. We also considered multiple exposure classifications with differing lag times between aspirin use and incident pancreatic cancer to thoroughly evaluate for potential associations.